Skip to main content
Premium Trial:

Request an Annual Quote

Merck KGaA, Millipore, PT Peptide Technologies

Premium
Germany's Merck KGaA to Use Cenix's RNAi Service to Screen for Drugs
 
Cenix BioScience this week said German drug maker Merck KGaA will use Cenix’s RNAi screening services in its target-discovery and -validation efforts in oncology, with an option to expand in several human disease programs.
 
Terms of the deal call for Cenix to perform high-throughput screens of cultured human cells to discover and validate new therapeutic targets, using assays co-designed with Merck scientists.
 
Financial terms of the deal were not disclosed.
 

 
Millipore to Market JPT Peptide's Enzyme Profiling Products
 
Millipore this week said that it will market and distribute JPT Peptide Technologies’ line of enzyme profiling products and services targeting enzymes such as kinases, phosphatases, and proteases.
 
JPT is a wholly owned subsidiary of Berlin-based Jerini. The non-exclusive deal is worldwide.
 
JPT's products “strongly complement our existing portfolio of cell signaling reagents and services,” Rick Ryan, vice president of the drug discovery business unit for the bioscience division of Millipore, said in a statement.
 
Financial terms of the deal were not disclosed.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.